- Email:
Alzheimer's Disease Modeling Service
Introduction
Alzheimer's disease modeling has advanced to humanized systems that focus on non-mutated human tau and temporal biomarkers such as plasma p-tau217. Creative Biolabs provides professional AD modeling services using iPSC-derived 3D organoids, secondary tauopathy models, and gene-edited animal systems. The company offers solutions covering neuroinflammation, BBB integrity, and synaptic loss, delivering validated models, biomarker data, and pharmacodynamic profiles to support reliable preclinical drug development and efficient clinical translation.
Discover How We Can Help - Request a Consultation →
Alzheimer's Disease Modeling
Etiology & Pathological Mechanisms
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by complex and interacting pathological pathways.
The amyloid cascade involves abnormal cleavage of the amyloid precursor protein (APP), leading to accumulation of toxic Aβ oligomers and extracellular senile plaques, triggering synaptic dysfunction and oxidative stress.
Hyperphosphorylated tau dissociates from microtubules and forms intracellular neurofibrillary tangles, disrupting axonal transport and inducing neuronal death.
Additional mechanisms include chronic neuroinflammation mediated by activated microglia and astrocytes, impaired autophagy-lysosomal function, mitochondrial damage, and genetic risks such as APP, PSEN1, PSEN2 mutations, and the APOE ε4 allele.
Alzheimer's Disease (AD) Common Research Models (Table)
| Model Category | Specific Model | Core Information (Cell/Animal, Establishment Method) | Advantages |
|---|---|---|---|
| Transgenic Mouse Models | APP/PS1 double transgenic mice | Mouse; co-expresses human APP (Swedish mutation) and PSEN1 (ΔE9 mutation), induces Aβ plaque deposition. |
1. Recapitulates core Aβ pathology; 2. Stable inheritance, high reproducibility; 3. Suitable for long-term pathogenesis research. |
| 5xFAD mice | Mouse carries 5 AD-related mutations (APP: 3, PSEN1: 2), rapid Aβ plaque formation (6-8 weeks old). |
1. Fast pathological progression, short experimental cycle; 2. Severe Aβ pathology, suitable for drug screening. |
|
| 3xTg-AD mice | Mouse expresses APP (Swedish), PSEN1 (M146V), tau (P301L), and recapitulates Aβ and tau dual pathology. |
1. Simultaneously models Aβ plaques and tau tangles; 2. Mimics cognitive decline, close to human AD progression. |
|
| Chemical-Induced Models | STZ-induced model | Rat/mouse; intracerebroventricular injection of STZ induces sporadic AD-like pathology. |
1. Simulates sporadic AD (most common type); 2. Simple operation, low cost; 3. Short modeling cycle. |
| Aβ oligomer injection model | Rat/mouse; injection of synthetic Aβ oligomers into the hippocampus/cortex induces synaptic dysfunction. |
1. Directly targets Aβ toxicity, suitable for Aβ-related mechanism research; 2. Fast modeling, high efficiency. |
|
| 2D Cell Models | Primary cortical/hippocampal neurons | Mouse/rat embryonic neurons; isolated from cortex/hippocampus, cultured in vitro. |
1. Physiologically close to in vivo neurons; 2. Suitable for studying synaptic function and neuronal toxicity. |
| PC-12 cells | Rat pheochromocytoma cell line; differentiates into neuron-like cells under NGF induction. |
1. Easy to culture, stable phenotype; 2. Suitable for preliminary study of neuronal damage and protection. |
|
| Human iPSC-derived neurons | Human iPSCs, differentiated into cortical/hippocampal neurons in vitro, can carry patient-specific mutations. |
1. Human-derived, high clinical relevance; 2. Patient-specific, suitable for personalized medicine research; 3. Long-term culture available. |
|
| Gene-edited neuronal cell lines | iPSC-derived neurons; edited with APP, PSEN1, tau mutations via CRISPR/Cas9. |
1. Stable expression of AD-related mutations; 2. High reproducibility, suitable for mechanism research and drug screening. |
|
| 3D Cell Models | Neurosphere cultures | Neural progenitor cells (NPCs), aggregated into spheres in vitro, differentiate into neurons/glia. |
1. Simulates cell-cell interactions; 2. Easy to prepare, suitable for preliminary 3D research. |
| Brain-on-a-chip models | Neurons/glia, cultured on microfluidic chips, simulate brain blood flow and cell interactions. |
1. Highly simulates in vivo brain microenvironment; 2. Real-time monitoring of cell function. |
|
| Human iPSC-derived brain organoids | Human iPSCs, differentiated into 3D brain/cortical organoids, recapitulate AD pathology (Aβ/tau). |
1. Human-derived, most similar to in vivo brain structure; 2. Recapitulates complete AD pathology; 3. Suitable for personalized medicine and preclinical trials. |
Workflow
The process begins with a deep technical consultation to align our modeling strategy with your molecule's specific Mechanism of Action (MoA). Whether you require high-throughput in vitro screening or complex in vivo behavioral studies, we customize every stage of the project.
What We Can Offer
As a global leader in neurobiology, Creative Biolabs provides a one-stop solution for Alzheimer's Disease Modeling, scaling from initial molecular pilot studies to large-scale industrial validation. We pride ourselves on offering fully customized services tailored to the unique biological signature of your therapeutic candidate.
One-stop Modeling Service
All-sided transition from laboratory-scale in vitro screening to pilot and large-scale in vivo efficacy studies.
Optimized Genetic Engineering
Expert codon usage optimization and CRISPR-mediated strain development to guarantee the stability of humanized genes across cell banks and large-scale cohorts.
Advanced Bioprocess Integration
Utilization of Quality-by-Design (QbD) and Process Analytical Techniques (PAT) to ensure the highest standard of reproducibility in pathological induction.
Customized Culture & Environmental Control
Optimization of culture conditions for iPSC-derived organoids and specialized housing for naturally aged populations to maximize physiological relevance.
Strict Quality Verification
Rigorous aseptic procedures and high-standard quality control tools to quantify Aβ 42:40 ratios and hyperphosphorylated tau levels with clinical-grade precision.
GMP-Compliant Data Standards
Documentation and procedures approved by qualified quality assurance services, adhering to the basic principles of Good Manufacturing Practice (GMP).
Flexible Operational Modes
Ability to run longitudinal studies in batch, fed-batch, or continuous monitoring modes depending on your drug's metabolic profile.
Experience the Creative Biolabs Advantage - Get a Quote Today →
Customer Reviews
FAQ
Q1: Why choose a Wild-Type tau model over conventional P301S transgenic mice?
A: Although P301S models exhibit rapid tau aggregation, they primarily model Frontotemporal Dementia (FTD) rather than Alzheimer's disease. WT-tau models better recapitulate the secondary tauopathy observed in human AD patients, resulting in significantly improved clinical translatability.
Q2: Can you integrate patient-specific mutations into iPSC-based models?
A: Yes. We use CRISPR/Cas9 gene editing to introduce familial AD mutations (such as PSEN1 or APP Swedish) or key risk alleles like APOE4 into isogenic cell lines, enabling controlled and direct comparative analyses.
Q3: How do you address high mortality in aggressive AD mouse models?
A: We implement optimized surgical procedures and dedicated post-operative care protocols tailored for stereotaxic infusion models, ensuring high animal welfare standards and consistent, reliable experimental data.
Q4: Are your 3D organoids compatible with high-throughput screening?
A: Yes. Our 3D cerebral organoids can be formatted for 96‑well or 384‑well plates, supporting automated high-content screening (HCS) for efficient compound library evaluation.
Creative Biolabs offers an end-to-end ecosystem for Alzheimer's research, from custom iPSC differentiation and 3D organoid culture to advanced behavioral phenotyping in double-humanized knock-in models. Our commitment to utilizing the most recent "Biomarker Clock" data and secondary tauopathy paradigms ensures that your preclinical assets are tested in the most human-relevant environments available today.
Contact Our Team for More Information and to Discuss Your Project →
For Research Use Only. Not For Clinical Use.